AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 211 min read$IART

IART: Flood disruption and Tissue softness weighed on outlook; cash and refinancing strengthened flexibility

Integra LifeSciences [IART] reported Q3 2026 growth and EPS gains, but these were offset by Cincinnati flooding and softness in Tissue Reconstruction. The company highlighted record cash flow, reduced leverage, and refinancing to enhance flexibility, with a focus on recovery and 2027 growth.

Original reporting
tradingview.com
Published Oct 21, 2026, 3:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 3:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
IART: Flood disruption and Tissue softness weighed on outlook; cash and refinancing strengthened flexibility — source image
Source · tradingview.com
Decision brief

The 30-second read

$IARTBearishMed
01

Why it matters

The guidance suggests a short‑term earnings drag, but the balance sheet strength may mitigate long‑term risk.

02

Market read

The earnings outlook directly affects IART and may influence peer med‑tech stocks.

03

What to watch

Potential cost‑saving initiatives and upcoming product launches are not discussed.

Relevance 7/10Novelty 7/10Timing: post‑earnings Q3 2026 release

Background

Integra LifeSciences (IART) released its Q3 2026 earnings summary, noting external disruptions and internal financial strength.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Q3 2026 earnings guidance shows tempered growth and EPS due to flooding and tissue softness, but record cash flow and lower leverage.

Expected impact

likely downside pressure as investors price in weaker outlook.

Evidence & confidence

The article provides the first report of the company's Q3 outlook, highlighting specific headwinds that could reduce near‑term earnings expectations.

Market effects

Sector

Medical device sector may see modest pressure as a mid‑cap player signals softer demand.

Regional

U.S. healthcare equities could experience slight pullback.

Global

Limited to investors tracking U.S. med‑tech stocks.

Counterpoint

What could challenge this read

The strong cash flow and refinancing flexibility could support a rebound if flood impacts are temporary.

Key entities

  • Company
    Integra LifeSciences Holdings Corporation

    U.S. medical device manufacturer (ticker IART).

Read at source← All news

StoryIntegra LifeSciences reports Q3 2026 results, cites $7 M flood hit, completes $2.1 B refinancing and trims Q4 outlook

Also covered by

6 outlets

Related articles

OCT 21
$IARTMed

Integra LifeSciences (IART) Reports Q3 Revenue In Line with Guid

Integra LifeSciences (IART) reported Q3 revenue of $411M, meeting the lower end of its guidance. The company lowered its full-year revenue outlook by $30M due to operational disruptions. IART's P/S ratio is 0.57, below historical and industry averages. The company has a GF Score of 69, indicating mixed fundamentals with strengths in momentum and profitability but weaknesses in growth and financial strength. Insider activity shows net buying of $0.1M, while institutional interest is mixed.

gurufocus.com3 min
OCT 21
$IARTHighAI 8/10

Integra (IART) Q3 2026 Earnings Call Transcript

Integra (IART) reported Q3 2026 adjusted EPS of $0.59, with revenue at $411.2M, impacted by Cincinnati flooding. Operating cash flow was $96M. Full-year revenue guidance was reduced by $30M due to flooding and mixed portfolio performance. Tissue Reconstruction revenue is expected to be flat. The company reduced leverage to 3.8x and completed debt refinancing, strengthening its balance sheet.

finance.yahoo.com3 min
OCT 21
$IARTHigh

Integra Life falls as tissue reconstruction woes add to flooding worries in Q3

Integra LifeSciences (IART) shares fell to a May low after Q3 2026 results missed revenue estimates. Revenue was $411.2M, up 2% YoY but below consensus by $0.9M, impacted by a $7M headwind and weaker Tissue Reconstruction performance. Gross margin declined 500 bps to 51%, while adjusted net income rose 12% YoY to $46.4M, beating estimates by $0.03 per share. Q4 and full-year outlooks were set below consensus.

tradingview.com2 min
OCT 21
Med

Integra LifeSciences Holdings Corporation Q3 2026 Earnings Call Summary

Integra LifeSciences reported Q3 2026 earnings, citing a $7M revenue hit from Cincinnati flooding. Neurosurgery grew 6.5% organically, offsetting weaker segments. Tissue Reconstruction showed mixed results. The company refinanced $2.1B in debt. Management expects 2027 revenue to be impacted by $15M-$20M in Q1 and Q2 due to ongoing disruption. Earnings growth is projected to be supported by cost savings and a SurgiMend relaunch.

finance.yahoo.com2 min
OCT 21
$IARTMed

Why Integra LifeSciences (IART) stock is falling today

Integra LifeSciences (IART) shares fell 7.3% after reporting Q3 revenue of $411.2M, meeting expectations, and adjusted EPS of $0.59, beating estimates. The company cited plant flooding and operational disruptions, projecting Q4 revenue of $413M-$433M, below analyst estimates of $433.2M. Rising borrowing costs also weighed on investor sentiment.

financialcontent.com2 min